Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma |
Myeong Jun Song |
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea |
Correspondence:
Myeong Jun Song, Email: mjsong95@gmail.com |
|
Abstract |
Transarterial chemoembolization (TACE) has been widely used as a standard treatment for HCC patients who are not suitable
candidates for curative treatments and as a bridge to liver transplantation. The rationale for TACE is that the intra-arterial
chemotherapy using lipiodol and chemotherapeutic agents, followed by selective vascular embolization, will result in a strong
cytotoxic effect combined with ischemia (conventional TACE). Recently, drug-eluting beads (DC Bead®) for the transcatheter
treatment of HCC have been developed to deliver higher doses of chemotherapeutic agent and to prolong contact time with the
tumor. DC Bead® has the ability to actively sequester doxorubicin hydrochloride from solution and release it in a controlled and
sustained fashion. Treatment with DC Bead® has been shown to substantially diminish the amount of chemotherapeutic agent that
reaches the systemic circulation compared with conventional, lipiodol-based regimens, significantly reducing drug-related
adverse events. In this article, we describe the treatment efficacy and safety of TACE with the drug-eluting bead for the treatment
of hepatocellular carcinoma and discuss future therapeutic possibilities. |
Key Words:
Hepatocellular carcinoma; Transarterial chemoembolization; Conventional TACE; Drug-eluting bead |
NULL |
|